AveXis – First patient dosed in Phase 1 trial of AVXS-101 in SMA Type

CHICAGO, Jan. 16, 2018 (GLOBE NEWSWIRE) — AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today provided an overview of the expanded clinical development program for the company’s initial gene therapy candidate, AVXS-101, for the treatment of spinal … Fortsätt läsa AveXis – First patient dosed in Phase 1 trial of AVXS-101 in SMA Type